UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 37.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 420,325 shares of the biopharmaceutical company's stock after purchasing an additional 113,872 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.32% of Dynavax Technologies worth $5,368,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently modified their holdings of DVAX. E Fund Management Co. Ltd. grew its position in Dynavax Technologies by 4.6% in the fourth quarter. E Fund Management Co. Ltd. now owns 17,627 shares of the biopharmaceutical company's stock valued at $225,000 after acquiring an additional 771 shares in the last quarter. Summit Investment Advisors Inc. increased its position in shares of Dynavax Technologies by 7.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 13,782 shares of the biopharmaceutical company's stock worth $176,000 after acquiring an additional 904 shares during the last quarter. Sanctuary Advisors LLC lifted its stake in shares of Dynavax Technologies by 6.3% in the fourth quarter. Sanctuary Advisors LLC now owns 18,836 shares of the biopharmaceutical company's stock worth $245,000 after acquiring an additional 1,109 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in Dynavax Technologies by 96.5% in the fourth quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 1,169 shares during the last quarter. Finally, Parkman Healthcare Partners LLC grew its stake in Dynavax Technologies by 0.7% during the 4th quarter. Parkman Healthcare Partners LLC now owns 220,980 shares of the biopharmaceutical company's stock valued at $2,822,000 after purchasing an additional 1,529 shares in the last quarter. Hedge funds and other institutional investors own 96.96% of the company's stock.
Dynavax Technologies Stock Performance
Shares of Dynavax Technologies stock traded down $0.12 during trading hours on Wednesday, reaching $9.89. The company's stock had a trading volume of 1,439,540 shares, compared to its average volume of 2,197,134. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. Dynavax Technologies Co. has a one year low of $9.22 and a one year high of $14.63. The company's 50 day simple moving average is $10.85 and its 200 day simple moving average is $12.28. The stock has a market cap of $1.19 billion, a P/E ratio of 54.94 and a beta of 1.26.
Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last issued its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of $0.03 by ($0.14). The company had revenue of $68.16 million during the quarter, compared to analyst estimates of $70.01 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. As a group, analysts expect that Dynavax Technologies Co. will post 0.32 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of equities analysts have issued reports on the company. The Goldman Sachs Group cut their target price on Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a research report on Thursday, April 17th. JMP Securities reduced their price objective on shares of Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating on the stock in a research note on Wednesday, May 7th. Wall Street Zen downgraded shares of Dynavax Technologies from a "buy" rating to a "hold" rating in a research report on Tuesday, May 6th. William Blair restated an "outperform" rating on shares of Dynavax Technologies in a research note on Friday, February 21st. Finally, HC Wainwright reiterated a "buy" rating and issued a $31.00 price target on shares of Dynavax Technologies in a research note on Friday, February 21st. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, Dynavax Technologies has an average rating of "Hold" and a consensus price target of $24.00.
Get Our Latest Analysis on DVAX
Dynavax Technologies Profile
(
Free Report)
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
Featured Articles
Before you consider Dynavax Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dynavax Technologies wasn't on the list.
While Dynavax Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
